677007-73-7

Usage

Uses

Used in Pharmaceutical Industry:
Ethanone, 2-bromo-1-(4-chloro-2-thienyl)is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, Ethanone, 2-bromo-1-(4-chloro-2-thienyl)- serves as an intermediate in the production of agrochemicals. Its properties make it suitable for the synthesis of pesticides and other agricultural chemicals, thereby playing a role in enhancing crop protection and yield.
Used in Organic Compound Production:
Ethanone, 2-bromo-1-(4-chloro-2-thienyl)is utilized as a building block in the creation of organic compounds. Its versatility in chemical reactions enables the formation of a wide range of organic molecules, which can be applied across various industries.
Safety Precautions:
Due to the potential health and safety risks associated with Ethanone, 2-bromo-1-(4-chloro-2-thienyl)-, it is essential to handle this chemical with caution. Proper safety measures, including the use of personal protective equipment and adherence to safety protocols, should be implemented to minimize risks during its use and manipulation.

Upstream product

• 34730-20-6 1-(4-chlorothiophen-2-yl)ethan-1-one 

Downstream Products

• 570407-10-2 4-(4-chlorothiophen-2-yl)-1,3-thiazol-2-amine 

Relevant academic research and scientific papers

Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis

Abstract The cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride channel present in the membrane of epithelial cells. Mutations affecting the CFTR gene cause cystic fibrosis (CF), a multi-organ severe disease. The most common CF mutation, F508del, impairs the processing and activity (gating) of CFTR protein. Other mutations, like G551D, only cause a gating defect. Processing and gating defects can be targeted by small molecules called generically correctors and potentiators, respectively. Aminoarylthiazoles (AATs) represent an interesting class of compounds that includes molecules with dual activity, as correctors and potentiators. With the aim to improve the activity profile of AATs, we have now designed and synthesized a library of novel compounds in order to establish an initial SAR that may provide indications about the chemical groups that are beneficial or detrimental for rescue activity. The new compounds were tested as correctors and potentiators in CFBE41o-expressing F508del-CFTR using a functional assay. A dual active compound, AAT-4a, characterized by improved efficacy and marked synergy when combined with the corrector VX-809 has been identified. Moreover, by computational methods, a possible binding site for AATs in nucleotide binding domain NBD1 has been detected. These results will direct the synthesis of new analogues with possibly improved activity.

2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF

A 2-acylaminothiazole derivative or a pharmaceutically acceptable salt thereof having an excellent effect of proliferating human c-mpl-Ba/F3 cells and an activity of increasing platelets based on the effect of promoting the formation of megakaryocytic colonies. A compound or a pharmaceutically acceptable salt thereof useful in treating thrombocytopenia.